景磊，男，汉族，中共党员，博士，讲师。2020年毕业于天津科技大学生物工程学院，获得工学博士学位，现承担细胞工程的课程。

科研领域及方向：

1.泛素化酶调控肿瘤发生和转移的分子机制研究。

2.寻找新型药物靶点，筛选具有抗肿瘤、免疫调节药物与分子药理学研究。

3.利用微生物发酵和细胞培养表达和制备基因工程蛋白质药物。

主要学术成果：

Jing L, Liu J, Cui D, et al. Screening and production of an affibody inhibiting the interaction of the PD-1/PD-L1 immune checkpoint[J]. Protein Expression and Purification, 2020,166.

Jing L, Yan F, Wang Y. et al. (2018) Establishment of the Method for Screening Small Molecule Inhibitors Blocking the Interaction Between PD-1 and Its Ligand PD-L1. In: Liu H., Song C., Ram A. (eds) Advances in Applied Biotechnology. ICAB 2016. Lecture Notes in Electrical Engineering, vol 444. Springer, Singapore.

景磊,赵苗苗,姜博,李玉银,刁爱坡.PD-L1表达抑制剂的筛选及其抗肿瘤活性[J].天津科技大学学报,2020,35(01):26-32.

刁爱坡,景磊,李玉银.一种黄酮类化合物的应用[P]. CN201910460460.5, 2019.

Luo S,Jing L(Co-first author), Zhao T, et al. Ubiquitination and dynactin regulate TMEPAI lysosomal trafficking[J]. Scientific Reports, 2017, 7:42668.

Bai X,Jing L(Co-first author), Li Y, et al. TMEPAI inhibits TGF-β signaling by promoting lysosome degradation of TGF-β receptor and contributes to lung cancer development[J]. Cellular Signalling, 2014, 26(9):2030-2039.

Dang J,Jing L, Shi W, et al. Expression and purification of active recombinant human bone morphogenetic 7-2 dimer fusion protein[J]. Protein Expression and Purification, 2015, 115:61-68.